Cagrisema Novo Nordisk

The next chapter in weight loss medication is being written right now. CagriSema Novo Nordisk's investigational drug combines two hormones) semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), into a single weekly injection. In clinical trials, this combination has produced up to 25 percent body weight loss, making it the most effective obesity medication ever studied.

Key Takeaways: - Understand what is cagrisema and how does it work - Clinical Trial Results: What the Data Shows - Side Effects and Safety Profile - Timeline, Availability, and What to Watch For

Here is what you need to know about CagriSema, how it works, what the trial data shows, and when it might become available.

What Is CagriSema and How Does It Work?

CagriSema is a fixed-ratio combination of two active compounds.

Semaglutide is the GLP-1 receptor agonist you may already know from weight management and diabetes treatment. It works by mimicking the GLP-1 hormone your gut releases after eating. This slows gastric emptying, increases insulin release, reduces glucagon, and acts on brain regions that control appetite and satiety. Semaglutide alone has shown about 15 to 17 percent average body weight loss in clinical trials.

Cagrilintide is a long-acting analog of amylin, a hormone released by the pancreas alongside insulin after meals. Amylin has several effects that complement GLP-1. It slows gastric emptying through a different pathway, reduces post-meal glucagon release, and acts on the area postrema and other brainstem regions to promote fullness.

The key insight behind CagriSema is that GLP-1 and amylin regulate appetite through different but complementary brain circuits. By activating both pathways at once, the combination produces stronger appetite suppression and greater weight loss than either hormone alone.

Think of it this way (semaglutide turns down the hunger signal through one set of pathways. Cagrilintide turns it down through a different set. Together, they reduce appetite more than either could independently.

"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.") Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding

For background on how GLP-1 medications work, see our .

Clinical Trial Results: What the Data Shows

The REDEFINE clinical trial program is testing CagriSema across multiple patient populations. The results so far have generated significant attention.

---

Free Download: GLP-1 Medication Comparison One-Pager Compare GLP-1 medications side by side (active ingredients, dosing schedules, and key differences. Get yours free) we'll email it to you instantly. [Download Now]

---

REDEFINE 1 was the key phase 3 trial in adults with obesity or overweight with at least one weight-related complication. After 68 weeks of treatment:

• CagriSema produced an average body weight loss of approximately 22 to 25 percent.
• Semaglutide alone (2.4 mg) produced about 16 percent weight loss in the comparator arm.
• Cagrilintide alone produced about 8 percent weight loss.
• The combination clearly outperformed either component on its own.

To put those numbers in context, a person weighing 250 pounds could expect to lose roughly 55 to 62 pounds on CagriSema over about 16 months. That level of weight loss approaches what is typically seen only with bariatric surgery.

REDEFINE 2 studied CagriSema in people with type 2 diabetes and obesity. The results showed strong A1C reductions alongside significant weight loss, suggesting the drug could address both conditions simultaneously.

How CagriSema compares to tirzepatide. No direct head-to-head trial between CagriSema and tirzepatide has been conducted. Tirzepatide (which combines GLP-1 and GIP receptor activation) has shown about 20 to 22 percent weight loss in its trials. CagriSema's numbers appear modestly higher, but differences in trial populations and design make direct comparison imperfect. For more on how current GLP-1 options compare, see our .

Side Effects and Safety Profile

CagriSema's side effect profile is broadly similar to other GLP-1 medications, though the combination does bring some nuances.

Gastrointestinal side effects remain the most common issue. Nausea, vomiting, diarrhea, and constipation were reported by a significant percentage of trial participants. Because both semaglutide and cagrilintide slow gastric emptying, the GI effects can be more pronounced than with semaglutide alone (at least during the initial dose escalation period.

Dose titration helps. CagriSema uses a slow dose escalation schedule specifically designed to reduce GI side effects. Most participants in the trials reported that nausea was worst in the first four to eight weeks and improved substantially after that.

Injection site reactions were reported at slightly higher rates than semaglutide alone, possibly because the injection volume is larger when combining two compounds. These were generally mild) redness, itching, or minor swelling at the injection site.

Discontinuation rates due to side effects were modestly higher than semaglutide alone in some trial arms, but the majority of participants completed the full treatment period. The very strong weight loss results likely motivated many participants to push through early side effects.

Serious adverse events including pancreatitis and gallbladder issues occurred at similar rates to other GLP-1 medications. The overall safety profile has not raised any new red flags specific to the amylin component.

For tips on managing GI side effects with GLP-1 medications, read our .

Ready to explore GLP-1 treatment options available now? .

Timeline, Availability, and What to Watch For

CagriSema is not yet available. Here is what we know about its path to market.

Regulatory submissions. Novo Nordisk has submitted CagriSema for FDA approval based on the REDEFINE program data. The FDA review process typically takes 10 to 12 months from submission. An approval decision could come in late 2026 or early 2027.

Manufacturing challenges. One reason Novo Nordisk is pursuing CagriSema aggressively is market positioning. They are investing billions in manufacturing capacity to avoid the supply shortages that plagued semaglutide during its rapid growth period. However, initial supply at launch may still be limited.

Insurance and cost. Pricing has not been announced, but CagriSema will likely be positioned as a premium product. Given the stronger weight loss results, some insurers may cover it for patients who have not achieved adequate results with existing GLP-1 monotherapy.

What you can do now. CagriSema is not available yet, but effective GLP-1 treatment options exist today. Compounded semaglutide and tirzepatide are available through licensed providers and 503A pharmacies. If weight management is your goal, there is no reason to wait (you can start building healthy habits and making progress now, and transition to newer medications if and when they become available.

Stay realistic about expectations. Clinical trial results represent averages. Some participants lost more than 25 percent of their body weight, and some lost less. Individual results depend on genetics, adherence, diet, exercise, and many other factors. No medication guarantees a specific outcome.

To see if you qualify for GLP-1 treatment available today, .

Frequently Asked Questions

When will CagriSema be available?

CagriSema is currently under FDA review. If approved, it could become available in late 2026 or early 2027. However, initial supply may be limited. Your provider can help you stay informed about availability as the launch approaches.

How is CagriSema different from tirzepatide?

CagriSema combines semaglutide (GLP-1) with cagrilintide (amylin analog), while tirzepatide combines GLP-1 with GIP receptor activation. They use different hormone combinations to enhance weight loss beyond what GLP-1 alone can achieve. No direct head-to-head trial has compared them, but CagriSema's phase 3 data suggests slightly higher average weight loss.

Will CagriSema replace semaglutide?

Not necessarily. Semaglutide remains an effective treatment for many people and may be preferred when side effect tolerance, cost, or insurance coverage are factors. CagriSema is likely to be positioned as an option for patients who need more aggressive weight management than semaglutide alone can provide.

Can I take CagriSema if I am already on semaglutide?

CagriSema already contains semaglutide, so you would not take both simultaneously. If CagriSema becomes available and your provider recommends it, you would transition from semaglutide monotherapy to the combination product. Your provider would manage the dosing transition.

What is amylin and why does adding it help with weight loss?

Amylin is a hormone your pancreas releases alongside insulin after meals. It slows digestion, reduces post-meal blood sugar spikes, and sends satiety signals to the brain through pathways different from GLP-1. By activating both the GLP-1 and amylin pathways, CagriSema suppresses appetite more effectively than targeting either pathway alone.

Ready to Take the Next Step?

Your health outcomes is personal) and you deserve a plan that fits. FormBlends connects you with licensed providers who can evaluate your needs and create a personalized protocol.

---

Sources & References

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
2. Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
5. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
6. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
9. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
10. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
11. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
12. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881

This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.

Last updated: 2026-03-24